和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

已收盘 10-22 16:08:35

10.170

-0.540

-5.04%

最高10.770	最低9.895	成交量1,579万
今开10.700	昨收10.710	日振幅8.17%
总市值88.48亿	流通市值88.48亿	总股本8.70亿
成交额1.62亿	换手率1.82%	流通股本8.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":10.17,"timestamp":1792656515004,"preClose":10.71,"halted":0,"volume":15794070,"delay":0,"changeRate":-0.050420168067226975,"floatShares":869999999,"shares":869999999,"eps":0.11,"marketStatus":"已收盘","change":-0.54,"latestTime":"10-22 16:08:35","open":10.7,"high":10.77,"low":9.895,"amount":162084476,"amplitude":0.081699,"askPrice":10.17,"askSize":21000,"bidPrice":10.16,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":0.762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792719000000},"marketStatusCode":5,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":10.71,"openAndCloseTimeList":[[1792632600000,1792641600000],[1792645200000,1792656000000]],"volumeRatio":1.579321,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/tweets","defaultTab":"tweets","newsList":[{"id":"1192834626","title":"异动解读｜和铂医药-B盘中下跌5.23%，报10.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192834626","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192834626?lang=zh_cn&edition=full","pubTime":"2026-10-22 10:59","pubTimestamp":1792637965,"startTime":"0","endTime":"0","summary":"10月22日，和铂医药-B盘中下跌5.23%，报10.15港元，成交额7214.02万港元。和铂医药-B所在的生物科技行业中，康方生物下跌7.7%，信达生物下跌4.32%，百济神州下跌2.07%，麦科医药-B上涨11.34%，云顶新耀下跌5.16%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008368742.USD","02616","159992","BK1574","01877","LU0455707207.USD","LU2097828714.EUR","LU1951186391.HKD","LU0348784397.USD","IE00BPRC5H50.USD","IE00B031HY20.USD","01177","06978","IBBQ","LU0348783233.USD","LU0456846285.SGD","LU0880133367.SGD","600109","LNGR","01801","IE00B0JY6N72.USD","LU0516422366.SGD","LU0540923850.HKD","09688","09926","LU0128526141.USD","BK1589","LU0417516571.SGD","MEDX","09995","BK1141","BK0183","LU0228659784.USD","KURE","02269","LU0516422440.USD","LU0823426308.USD","LU1303224171.USD","LU1226288170.HKD","LU1770034418.SGD","06160","LU1794554557.SGD","KCE","06185","LU1807302812.USD","01093","02142","LU0128522744.USD","LU0588546209.SGD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127112844","title":"和铂医药-B：10月20日回购30万股，涉资约314.08万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127112844","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127112844?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:06","pubTimestamp":1792490781,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年10月20日发布公告，披露当日通过香港联交所场内回购30万股普通股，占回购前已发行股本约0.0345%，每股回购价介乎港币10.34元至10.50元，总金额约314.08万港元。回购完成后，公司库藏股数量增至34,534,000股。公告显示，和铂医药-B于2026年6月25日通过回购授权，授权回购总额为86,823,672股。根据相关规定，公司新股发行及库藏股再出售的暂止期将持续至2026年11月19日。公司确认已遵守香港联交所证券上市规则及其他相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和铂医药-B：10月20日回购30万股，涉资约314.08万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2676664561","title":"和铂医药-B(02142)10月20日斥资314.08万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676664561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676664561?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:05","pubTimestamp":1792490753,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，该公司于2026年10月20日斥资314.08万港元回购30万股股份，每股回购价格为10.34-10.5港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676220775","title":"和铂医药-B于10月16日斥资314.94万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2676220775","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676220775?lang=zh_cn&edition=full","pubTime":"2026-10-18 19:53","pubTimestamp":1792324380,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与项飙现场对话！\n名额有限，手慢无。让我们共赴可持续之约！【点击报名】和铂医药-B（02142）发布公告，于2026年10月16日，该公司斥资314.94万港元回购30万股股份，每股回购价10.24-10.66港元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-10-18/doc-inivrzvi7775812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124389277","title":"和铂医药-B回购30万股股份，总额约314.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124389277","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124389277?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:24","pubTimestamp":1792142692,"startTime":"0","endTime":"0","summary":"和铂医药-B于2026年10月16日公告，披露当日进行股份回购及已发行股份变动。根据公告，公司当日回购30万股普通股，占当日已发行股本约0.0345%，最高回购价为每股10.66港元，最低回购价为每股10.24港元，涉资总额约314.94万港元。回购的股份将作为库存股份持有。本次变动后，公司已发行股份总数为870,089,522股，库存股份合计34,234,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B回购30万股股份，总额约314.94万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162556343","title":"异动解读｜和铂医药-B盘中上涨5.54%，连续回购叠加板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1162556343","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162556343?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:36","pubTimestamp":1792114595,"startTime":"0","endTime":"0","summary":"10月16日，和铂医药-B盘中上涨5.54%，报10.56港元，成交额816.75万港元。消息面上，公司10月15日回购70万股，耗资约699.65万港元；10月13日至15日已连续3个交易日各回购70万股，合计回购210万股，累计金额约2146.55万港元，向市场释放维护股东回报的信号。同时，生物科技板块同步活跃，百济神州涨5.57%，科伦博泰生物涨5.25%，信达生物涨4.27%，对股价形成共振支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药连续回购，股价强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675546035","title":"【券商聚焦】中信建投：ESMO中国研究入选创新高 梳理医药细分板块机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2675546035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675546035?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:27","pubTimestamp":1792114033,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示，本周制药行业表现一般，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医疗器械及服务板块低值耗材表现较好，多受个股事件催化，科技概念标的调整，港股回购活跃；短期关注招标改善和集采出清，中长期看创新、出海、并购。中药板块跑赢申万医药及大盘，关注红利、创新及“四同药品”、中成药集采政策。生物制品板块跑输医药指数及大盘，AI制药、mRNA肿瘤疫苗概念股回调；南北方ILI%均环比降低，南方检测阳性率提升、北方降低。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993829","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","01801","02269","KURE","LU0140636845.USD","LU1226287792.SGD","01093","09995","LU2476274720.SGD","01877","BK1515","06185","LU0348827113.USD","LU0819121731.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0348767384.USD","LU1951186391.HKD","BK1583","06160","SG9999011746.SGD","02142","LU0979878070.USD","601066","09688","LU0326950275.SGD","LU1251922891.USD","LU0634319403.HKD","159938","LU0417516902.SGD","KCE","BK1610","LU0052750758.USD","01177","LU0181495838.USD","LU0823426480.USD","02616","BK1500","LU0314109678.HKD","LU1226287875.USD","09939","LU0359201612.USD","LU0228659784.USD","09926","BK1141","LU0072913022.USD","LU0128526141.USD","LU0540923850.HKD","LU1242518857.USD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135154702","title":"和铂医药-B于10月15日回购70万股股份，总额约699.65万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135154702","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135154702?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:41","pubTimestamp":1792068081,"startTime":"0","endTime":"0","summary":"公告显示，公司当日通过香港联交所场内回购普通股70万股，占该次变动前现有已发行股份总数约0.0804%，每股回购价格介乎每股9.83港元至10.42港元，合计耗资约699.65万港元。同时，公司根据于2020年11月23日采纳并获股东批准的首次公开发售后股份奖励计划，发行了5.3万股普通股，约占该次变动前已发行股份总数的0.006%。发行完成后，公司已发行股本增至870,340,522股，库藏股增至33,934,000股，总股本达904,274,522股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B于10月15日回购70万股股份，总额约699.65万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675582116","title":"和铂医药-B(02142.HK)10月15日斥资699.65万港元回购70万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675582116","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675582116?lang=zh_cn&edition=full","pubTime":"2026-10-15 20:37","pubTimestamp":1792067868,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675811415","title":"GIC Private Limited减持和铂医药(02142)75.3万股 每股作价约10.37港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675811415","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675811415?lang=zh_cn&edition=full","pubTime":"2026-10-15 19:14","pubTimestamp":1792062862,"startTime":"0","endTime":"0","summary":"10月13日，GIC Private Limited减持和铂医药(02142)75.3万股，每股作价10.3711港元，总金额约为780.94万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20261015/20261015191452_45033.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20261015/20261015191452_45033.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1574","02142","BK1161","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376082","title":"【券商聚焦】中信建投：AI重塑药物研发 2035年全球市场有望破460亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376082","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376082?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:00","pubTimestamp":1792026019,"startTime":"0","endTime":"0","summary":"AI深度介入靶点识别、分子设计等药物研发环节，破解传统制药高投入、长周期难题。报告测算，全球AI制药市场2025年规模约24.9亿美元，2035年有望突破460亿美元，CAGR超33%，国内市场具备高增长潜力；科技巨头、药企、CXO等多方入局，海内外多家头部企业完成平台搭建与商业化验证。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993729","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","LU0456846285.SGD","BK1141","LU1152091754.HKD","01801","IE00BZ08YS42.EUR","KCE","02616","KURE","LU0051755006.USD","LU0128526141.USD","CHAT","02142","BK1576","LU1008478684.HKD","601066","LU1251922891.USD","LU0516422952.EUR","09995","BK1500","QTOC","LU0516422440.USD","LU2242644610.SGD","BK1588","LU0456827905.SGD","LU0128522744.USD","LU0588546209.SGD","AGIX","LU0856984785.SGD","VTHR","ARTY","LU0348825331.USD","01877","09688","LU0516423174.USD","06185","LU0326950275.SGD","LU0029874061.USD","LU0052750758.USD","LU0979878070.USD","LU2778985437.USD","09926","01093","SG9999002562.SGD","AIPO","06160","02269","01177","LU0501845795.SGD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171962376","title":"和铂医药-B回购70万股，耗资约719.14万港元并发行12,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1171962376","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171962376?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:02","pubTimestamp":1791975738,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年10月14日刊发公告，披露当日于香港联交所回购普通股700,000股，占回购前已发行股份约0.0803%。本次回购的最高价格每股10.59港元，最低价格每股10.08港元，合计耗资约719.14万港元。公司同时根据2020年11月23日采纳并获股东批准的首次公开发售后股份奖励计划，向相关参与人额外发行普通股12,000股，占发行时已发行股份约0.0014%，每股发行价为0港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B回购70万股，耗资约719.14万港元并发行12,000股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675352423","title":"和铂医药-B(02142.HK)10月13日斥资727.76万港元回购70万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675352423","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675352423?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:02","pubTimestamp":1791896538,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118282167","title":"和铂医药-B回购70万股股份，总额约727.76万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118282167","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118282167?lang=zh_cn&edition=full","pubTime":"2026-10-13 21:01","pubTimestamp":1791896463,"startTime":"0","endTime":"0","summary":"公告显示，公司于2026年10月13日在香港联交所场内回购股份70万股，约占回购前已发行股本的0.08%。回购价格区间介乎每股10.21港元至10.53港元，涉及总金额727.76万港元。同期，公司根据于2020年11月23日采纳并经股东批准的首次公开发售后股份奖励计划，自2026年10月2日至2026年10月13日，先后发行普通股合计27.4万股用于满足股份奖励，分别占回购前已发行股本的约0.0023%至0.0092%不等。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B回购70万股股份，总额约727.76万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161930292","title":"异动解读｜和铂医药-B盘中下跌5.61%，生物科技板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1161930292","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161930292?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:42","pubTimestamp":1791855778,"startTime":"0","endTime":"0","summary":"10月13日，和铂医药-B盘中下跌5.61%，报10.26港元，成交额1344.1万港元。港股生物科技板块延续弱势，AI制药概念相关个股普遍承压，公司股价随板块系统性回调。参考信息显示，10月7日恒生生物科技指数一度跌超4%，和铂医药当日跌超5%；10月9日该股再度下跌5.51%，主力资金净流出1217.06万港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和铂医药随板块走弱，生物科技承压回调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198677384","title":"一周港股牛熊榜 | 利好消息推动两股周内飙逾27%！白鸽在线推进H股全流通，本末科技牵手稀土巨头；金界控股遭美银降级，周跌18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198677384","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198677384?lang=zh_cn&edition=full","pubTime":"2026-10-10 08:59","pubTimestamp":1791593943,"startTime":"0","endTime":"0","summary":"总结全周，港股个股表现分化，华夏文化科技本周累升39.00%领涨；中环新能源累计下跌22.83%，为榜单中表现最弱个股。相关方案仍须经股东大会批准，并取得中国证监会备案及联交所批准后方可实施。该行指出，金界控股博彩收入增长持续放缓，由第一季度同比增长2.1%，转为第二季度下跌20%、第三季度下跌43%，短期内博彩收入复苏的能见度有限。业务方面，中环新能源正推进新能源与AI算力业务协同发展。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02672","06731","02442","02142","01566","09900","01735","03918","07666","02768"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1118780256","title":"异动解读｜和铂医药-B盘中下跌5.09%，生物科技板块连续第三日承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1118780256","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118780256?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:37","pubTimestamp":1791509874,"startTime":"0","endTime":"0","summary":"10月9日，和铂医药-B盘中下跌5.09%，报11.21港元，成交额1168.02万港元。该股已连续第三个交易日显著走低，生物科技板块整体疲弱构成主要拖累。该行观点持续压制全球生物科技板块风险偏好，港股创新药标的联动走弱。同日板块内，康希诺生物跌5.12%，康方生物跌2.74%，百济神州跌2.72%，信达生物跌1.84%，三生制药逆势微涨0.4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技承压，和铂医药连续走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168638364","title":"异动解读｜和铂医药-B盘中下跌5.93%，生物科技板块集体调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1168638364","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168638364?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:36","pubTimestamp":1791423416,"startTime":"0","endTime":"0","summary":"10月8日，和铂医药-B盘中下跌5.93%，报12.06港元，成交额2179.96万港元。与此同时，生物科技板块整体承压。前一日隔夜美股医药板块暴跌，拖累港股医药股表现，和铂医药-B在板块联动下延续调整态势。和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司，通过专有抗体技术平台提供下一代抗体及生物解决方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"和铂医药盘中下挫，生物科技板块承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159576836","title":"和铂医药-B9月股份变动月报：新增发行2,837,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1159576836","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159576836?lang=zh_cn&edition=full","pubTime":"2026-10-08 06:21","pubTimestamp":1791411704,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年10月8日发布截至2026年9月30日止月份的股份变动月报。报告期内，公司法定/注册股本未发生变动，期末法定/注册股本仍为20,000,000,000股普通股，每股面值0.000025美元，法定/注册股本总额维持在500,000美元。本月末公司已发行股份较上月末增加2,837,000股，由869,264,522股增至872,101,522股。公司当月库存股份数为31,834,000股未发生变化，故本月末已发行股份总数为903,935,522股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.05},{"period":"1month","weight":-0.2945},{"period":"3month","weight":-0.1328},{"period":"6month","weight":-0.235},{"period":"1year","weight":-0.1806},{"period":"ytd","weight":-0.1192}],"compareEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":-0.0555},{"period":"3month","weight":-0.0618},{"period":"6month","weight":-0.0895},{"period":"1year","weight":-0.0913},{"period":"ytd","weight":-0.0772}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.053076},{"month":8,"riseRate":0.333333,"avgChangeRate":0.031233},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.057848},{"month":10,"riseRate":0,"avgChangeRate":-0.188451},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}